Inhibitory effects of diarsenic trioxide (As2O3) on hepatocellular carcinoma cells exerted by regulation of promyelocytic leukemia protein levels
DOI:
https://doi.org/10.14393/BJ-v39n0a2023-63086Palavras-chave:
As2O3, Hepatocellular carcinoma, Promyelocytic leukemia (PML). , Transcription factor 4.Resumo
Previous Chinese research revealed that diarsenic trioxide (As2O3) inhibits acute promyelocytic leukemia (PML) cell proliferation and initiates apoptosis through degradation of the PML-retinoic acid receptor protein. This study was to analyse whether As2O3 also had an effect on hepatocellular carcinoma (HCC) cells. As2O3 effects on various HCC cell lines and primary HCC cells were investigated in time and dose series, including measurements of cell growth, PML mRNA and protein expression, xenografted tumor formation, and the self-renewal Oct4 and hepatocyte marker expressions in mouse model xenografts or cells treated with PML siRNA. The results were analyzed by immunocytochemistry, quantitative reverse transcription PCR and western blotting as well as indocyanine green and Periodic Acid Schiff staining. As2O3 inhibited HCC cell and HCC cell-derived xenograft tumor formation in a time-dependent manner and reduced PML protein expression in HCC cells, but had limited effects on PML mRNA levels in cell nuclei. The HCC cell line HuH7 treated with As2O3 showed a decreased expression of alpha-fetoprotein and increased expression and transcription of mature hepatocyte markers, indicating differentiation of HCC cells into hepatocytes. Cytokeratin 18 protein and mRNA levels as well as tyrosine aminotransferase and apolipoprotein B mRNA transcriptions were enhanced by As2O3 as were the numbers of indocyanine green and Periodic Acid Schiff stained cells. In addition, As2O3 downregulated the expression of Oct4. In conclusion, since As2O3 inhibited HCC cell proliferation and HCC cell-derived xenograft tumor formation it is suggested that an appropriate concentration of As2O3 might be a promising therapy to treat HCC.
Downloads
Referências
ALIMOGHADDAM, K., et al. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia. Leukemia & lymphoma. 2006, 47(1), 81-88. https://doi.org/10.1080/10428190500300373
ALIMOGHADDAM, K. A review of arsenic trioxide and acute promyelocytic leukemia. International Journal of Hematology-Oncology and Stem Cell Research. 2014, 8(3), 44-54.
BAI, D.M. and ZHENG, X.F. PML-RARA mutations confer varying arsenic trioxide resistance. Protein & Cell. 2017, 8(4), 296-301. https://doi.org/10.1007/s13238-016-0356-4
CHEN, D.C., et al. CBFA2T2 is associated with a cancer stem cell state in renal cell carcinoma. Cancer Cell International. 2017, 17(103. https://doi.org/10.1186/s12935-017-0473-z
CHUANG, Y.S., et al. Promyelocytic leukemia protein in retinoic acid-induced chromatin remodeling of Oct4 gene promoter. Stem Cells (Dayton, Ohio). 2011, 29(4), 660-669. https://doi.org/10.1002/stem.623
COLLINS, A.T., et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research. 2005, 65(23), 10946-10951. https://doi.org/10.1158/0008-5472.can-05-2018
CUI, J., et al. All-trans retinoic acid inhibits proliferation, migration, invasion and induces differentiation of hepa1-6 cells through reversing EMT in vitro. International Journal of Oncology. 2016, 48(1), 349-357. https://doi.org/10.3892/ijo.2015.3235
FERLAY, J., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015, 136(5), E359-386. https://doi.org/10.1002/ijc.29210
FERRANDINA, G., et al. Expression of CD133-1 and CD133-2 in ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society.. 2008, 18(3), 506-514. https://doi.org/10.1111/j.1525-1438.2007.01056.x
FLENGHI, L., et al. Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. Blood. 1995, 85(7), 1871-1880.
GOLABI, P., et al. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine. 2017, 96(9), e5904. https://doi.org/10.1097/MD.0000000000005904
HARAGUCHI, N., et al. CD13 is a therapeutic target in human liver cancer stem cells. The Journal of Clinical Investigation. 2010, 120(9), 3326-3339. https://doi.org/10.1172/JCI42550
HERMANN, P.C., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007, 1(3), 313-323. https://doi.org/10.1016/j.stem.2007.06.002
IKEDA, S., NAGATA, C. and SUZUKI, K. Periodic acid Schiff staining-positive spermatocytic seminoma. Pathology International. 2014, 64(4), 192-194. https://doi.org/10.1111/pin.12150
ISHIZAWA, T., et al. Mechanistic background and clinical applications of indocyanine green fluorescence imaging of hepatocellular carcinoma. Annals of Surgical Oncology. 2014, 21(2), 440-448. https://doi.org/10.1245/s10434-013-3360-4
ITO, K., et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008, 453(7198), 1072-1078. https://doi.org/10.1038/nature07016
JEANNE, M., et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 2010, 18(1), 88-98. https://doi.org/10.1016/j.ccr.2010.06.003
KELLNER, S. and KIKYO, N. Transcriptional regulation of the Oct4 gene, a master gene for pluripotency. Histology and Histopathology. 2010, 25(3), 405-412. https://doi.org/10.14670/HH-25.405
KOO, B., et al. Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells. Oncogene. 2015, 34(18), 2317.
LIU, Z.M., et al. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells. The Biochemical Journal. 2011, 438(2), 349-358. https://doi.org/10.1042/BJ20101653
NAKAHARA, F., WEISS, C.N. and ITO, K. The role of PML in hematopoietic and leukemic stem cell maintenance. International Journal of Hematology. 2014, 100(1), 18-26. https://doi.org/10.1007/s12185-014-1518-x
NIWA, H., MIYAZAKI, J. and SMITH, A.G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nature Genetics. 2000, 24(4), 372-376. https://doi.org/10.1038/74199
O'BRIEN, C.A., et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007, 445(7123), 106-110. https://doi.org/10.1038/nature05372
QU, F.L., et al. [Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 2011, 33(9), 697-701.
RICCI-VITIANI, L., et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007, 445(7123), 111-115. https://doi.org/10.1038/nature05384
SINGH, S.K., et al. Identification of human brain tumour initiating cells. Nature. 2004, 432(7015), 396-401. https://doi.org/10.1038/nature03128
SUETSUGU, A., et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochemical and Biophysical Research Communications. 2006, 351(4), 820-824. https://doi.org/10.1016/j.bbrc.2006.10.128
TORRE, L.A., et al. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2015, 65(2), 87-108. https://doi.org/10.3322/caac.21262
VITALIANO-PRUNIER, A., et al. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation. Blood. 2014, 124(25), 3772-3780. https://doi.org/10.1182/blood-2014-03-561852
WANG, Q.Q., et al. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARalpha protein degradation. Oncotarget. 2015, 6(28), 25646-25659. https://doi.org/10.18632/oncotarget.4662
WANG, M., et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2017, 65(15-21. https://doi.org/10.1016/j.ijid.2017.09.003
WEI, J., et al. All-trans retinoic acid and arsenic trioxide induce apoptosis and modulate intracellular concentrations of calcium in hepatocellular carcinoma cells. Journal of Chemotherapy (Florence, Italy). 2014, 26(6), 348-352. https://doi.org/10.1179/1973947814Y.0000000200
WOO, S.H., et al. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. International Journal of Oncology. 2002, 21(1), 57-63.
YOSHIDA, H., et al. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Research. 1996, 56(13), 2945-2948.
ZEINEDDINE, D., et al. The Oct4 protein: more than a magic stemness marker, Am J Stem Cells. 2014, 3(2), 74-82.
ZHANG, X.W., et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science (New York, N.Y.). 2010, 328(5975), 240-243. https://doi.org/10.1126/science.1183424
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2023 Guowu Zhang, Wei Wang, Yukai Jin, Shilong Jin, Lei Mi, Xiaowen Song, He Li, Juan Liao
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
